Compare BORR & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | AMLX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2017 | 2021 |
| Metric | BORR | AMLX |
|---|---|---|
| Price | $4.43 | $15.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.25 | ★ $21.56 |
| AVG Volume (30 Days) | ★ 10.1M | 1.2M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $21.67 | N/A |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $1.81 | $4.86 |
| 52 Week High | $6.66 | $18.61 |
| Indicator | BORR | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 59.48 |
| Support Level | $4.16 | $12.17 |
| Resistance Level | $4.55 | $15.37 |
| Average True Range (ATR) | 0.23 | 0.88 |
| MACD | -0.06 | 0.28 |
| Stochastic Oscillator | 5.88 | 79.48 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.